PET/CT helps gauge patient response to neoadjuvant chemotherapy

04/10/2013 | AuntMinnie.com (free registration)

A study presented at a radiology meeting found that FDG-PET/CT has the potential to predict patient response following neoadjuvant chemotherapy for breast cancer. Researchers said the results suggest the assessment could be useful for guiding treatment decisions. The researchers used Sinn scores and two algorithms to measure patient response. An 88% change in maximum standardized uptake value is the appropriate cutoff to distinguish lesions that respond to treatment, they reported.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA